B-Cell	0	5	Tumor	Tumor	NN	B-NP
I-Cell	6	17	endothelial	endothelial	JJ	I-NP
I-Cell	18	22	cell	cell	NN	I-NP
O	23	31	targeted	target	VBD	B-VP
O	32	38	cyclic	cyclic	JJ	B-NP
O	39	42	RGD	RGD	NN	I-NP
O	42	43	-	-	HYPH	B-VP
O	43	51	modified	modify	VBN	B-NP
O	52	59	heparin	heparin	NN	I-NP
O	60	70	derivative	derivative	NN	I-NP
O	70	71	:	:	:	O
O	72	82	inhibition	inhibition	NN	B-NP
O	83	85	of	of	IN	B-PP
O	86	98	angiogenesis	angiogenesis	NN	B-NP
O	99	102	and	and	CC	I-NP
B-Cancer	103	108	tumor	tumor	NN	I-NP
O	109	115	growth	growth	NN	I-NP
O	115	116	.	.	.	O

O	117	124	PURPOSE	PURPOSE	NN	B-NP
O	124	125	:	:	:	O
O	126	128	We	We	PRP	B-NP
O	129	137	prepared	prepare	VBD	B-VP
B-Tissue	138	143	tumor	tumor	NN	B-NP
I-Tissue	144	155	endothelium	endothelium	NN	I-NP
O	156	164	targeted	target	VBD	B-VP
O	165	169	cRGD	cRGD	NN	B-NP
O	169	170	-	-	HYPH	O
O	170	178	modified	modify	VBN	B-NP
O	179	186	heparin	heparin	NN	I-NP
O	187	197	derivative	derivative	NN	I-NP
O	198	199	(	(	(	O
O	199	203	cRGD	cRGD	NN	B-NP
O	203	204	-	-	HYPH	B-NP
O	204	206	HL	HL	NN	I-NP
O	206	207	)	)	)	O
O	208	210	by	by	IN	B-PP
O	211	219	coupling	couple	VBG	B-VP
O	220	227	heparin	heparin	NN	B-NP
O	227	228	-	-	HYPH	O
O	228	239	lithocholic	lithocholic	JJ	B-NP
O	240	244	acid	acid	NN	I-NP
O	245	246	(	(	(	O
O	246	248	HL	HL	NN	B-NP
O	248	249	)	)	)	O
O	250	254	with	with	IN	B-PP
O	255	261	cRGDyK	cRGDyK	NN	B-NP
O	261	262	,	,	,	O
O	263	266	and	and	CC	O
O	267	276	evaluated	evaluate	VBN	B-NP
O	277	287	inhibition	inhibition	NN	I-NP
O	288	295	effects	effect	NNS	I-NP
O	296	298	of	of	IN	B-PP
O	299	303	cRGD	cRGD	NN	B-NP
O	303	304	-	-	HYPH	B-NP
O	304	306	HL	HL	NN	I-NP
O	307	309	on	on	IN	B-PP
O	310	322	angiogenesis	angiogenesis	NN	B-NP
O	323	326	and	and	CC	I-NP
B-Cancer	327	332	tumor	tumor	NN	I-NP
O	333	339	growth	growth	NN	I-NP
O	339	340	.	.	.	O

O	341	348	METHODS	METHODS	NNS	B-NP
O	348	349	:	:	:	O
O	350	352	To	To	TO	B-VP
O	353	361	evaluate	evaluate	VB	I-VP
O	362	376	antiangiogenic	antiangiogenic	JJ	B-NP
O	377	385	activity	activity	NN	I-NP
O	386	388	of	of	IN	B-PP
O	389	393	cRGD	cRGD	NN	B-NP
O	393	394	-	-	HYPH	B-NP
O	394	396	HL	HL	NN	I-NP
O	396	397	,	,	,	O
O	398	400	we	we	PRP	B-NP
O	401	410	performed	perform	VBD	B-VP
O	411	416	tests	test	NNS	B-NP
O	417	419	on	on	IN	B-PP
B-Cell	420	431	endothelial	endothelial	JJ	B-NP
I-Cell	432	436	cell	cell	NN	I-NP
O	437	445	adhesion	adhesion	NN	I-NP
O	446	449	and	and	CC	O
O	450	459	migration	migration	NN	B-NP
O	460	462	to	to	TO	B-PP
O	463	474	vitronectin	vitronectin	NN	B-NP
O	474	475	,	,	,	O
B-Tissue	476	480	tube	tube	NN	B-NP
O	481	490	formation	formation	NN	I-NP
O	490	491	,	,	,	O
O	492	499	binding	binding	NN	B-NP
O	500	508	affinity	affinity	NN	I-NP
O	509	511	to	to	TO	B-PP
O	512	520	purified	purify	VBN	B-NP
O	521	526	alpha	alpha	NN	I-NP
O	526	527	(	(	(	O
O	527	528	v	v	NN	B-NP
O	528	529	)	)	)	O
O	529	533	beta	beta	NN	B-NP
O	533	534	(	(	(	O
O	534	535	3	3	CD	B-NP
O	535	536	)	)	)	O
O	537	545	integrin	integrin	NN	B-NP
O	545	546	,	,	,	O
O	547	550	and	and	CC	O
O	551	553	in	in	FW	B-NP
O	554	558	vivo	vivo	FW	I-NP
O	559	567	Matrigel	Matrigel	NNP	I-NP
O	568	572	plug	plug	NN	I-NP
O	573	578	assay	assay	NN	I-NP
O	578	579	.	.	.	O

O	580	583	The	The	DT	B-NP
B-Cancer	584	593	antitumor	antitumor	JJ	I-NP
O	594	602	activity	activity	NN	I-NP
O	603	605	of	of	IN	B-PP
O	606	610	cRGD	cRGD	NN	B-NP
O	610	611	-	-	HYPH	B-NP
O	611	613	HL	HL	NN	I-NP
O	614	617	was	be	VBD	B-VP
O	618	622	also	also	RB	I-VP
O	623	632	evaluated	evaluate	VBN	I-VP
O	633	635	by	by	IN	B-PP
O	636	646	monitoring	monitor	VBG	B-VP
B-Cancer	647	652	tumor	tumor	NN	B-NP
O	653	659	growth	growth	NN	I-NP
O	660	663	and	and	CC	O
B-Tissue	664	675	microvessel	microvessel	NN	B-NP
O	676	685	formation	formation	NN	I-NP
O	686	688	in	in	IN	B-PP
B-Cancer	689	697	squamous	squamous	JJ	B-NP
I-Cancer	698	702	cell	cell	NN	I-NP
I-Cancer	703	712	carcinoma	carcinoma	NN	I-NP
I-Cancer	713	714	(	(	(	O
I-Cancer	714	718	SCC7	SCC7	NN	B-NP
I-Cancer	718	719	)	)	)	O
I-Cancer	720	725	tumor	tumor	NN	B-NP
O	725	726	.	.	.	O

O	727	734	RESULTS	RESULTS	NNS	B-NP
O	734	735	:	:	:	O
O	736	739	The	The	DT	B-NP
O	740	744	cRGD	cRGD	NN	I-NP
O	744	745	-	-	HYPH	O
O	745	747	HL	HL	NN	B-NP
O	748	761	significantly	significantly	RB	B-ADVP
O	762	771	inhibited	inhibit	VBD	B-VP
O	772	780	adhesion	adhesion	NN	B-NP
O	781	784	and	and	CC	I-NP
O	785	794	migration	migration	NN	I-NP
O	795	797	of	of	IN	B-PP
B-Cell	798	809	endothelial	endothelial	JJ	B-NP
I-Cell	810	815	cells	cell	NNS	I-NP
O	816	818	to	to	TO	B-PP
O	819	830	vitronectin	vitronectin	NN	B-NP
O	830	831	,	,	,	O
O	832	835	and	and	CC	O
B-Tissue	836	843	tubular	tubular	JJ	B-NP
I-Tissue	844	854	structures	structure	NNS	I-NP
O	855	857	of	of	IN	B-PP
B-Cell	858	869	endothelial	endothelial	JJ	B-NP
I-Cell	870	875	cells	cell	NNS	I-NP
O	875	876	.	.	.	O

O	877	885	Compared	Compare	VBN	B-PP
O	886	888	to	to	TO	B-PP
O	889	895	cRGDyK	cRGDyK	NN	B-NP
O	896	899	and	and	CC	I-NP
O	900	902	HL	HL	NN	I-NP
O	902	903	,	,	,	O
O	904	908	cRGD	cRGD	NN	B-NP
O	908	909	-	-	HYPH	B-NP
O	909	911	HL	HL	NN	I-NP
O	912	915	has	have	VBZ	B-VP
O	916	920	high	high	JJ	B-NP
O	921	928	binding	binding	NN	I-NP
O	929	937	affinity	affinity	NN	I-NP
O	938	940	to	to	TO	B-PP
O	941	949	purified	purify	VBN	B-NP
O	950	955	alpha	alpha	NN	I-NP
O	955	956	(	(	(	O
O	956	957	v	v	NN	B-NP
O	957	958	)	)	)	O
O	958	962	beta	beta	NN	B-NP
O	962	963	(	(	(	O
O	963	964	3	3	CD	B-NP
O	964	965	)	)	)	O
O	966	974	integrin	integrin	NN	B-NP
O	974	975	.	.	.	O

O	976	979	The	The	DT	B-NP
O	980	988	enhanced	enhance	VBN	I-NP
O	989	1003	antiangiogenic	antiangiogenic	JJ	I-NP
O	1004	1010	effect	effect	NN	I-NP
O	1011	1013	of	of	IN	B-PP
O	1014	1018	cRGD	cRGD	NN	B-NP
O	1018	1019	-	-	HYPH	I-NP
O	1019	1021	HL	HL	NN	B-NP
O	1022	1025	was	be	VBD	B-VP
O	1026	1035	confirmed	confirm	VBN	I-VP
O	1036	1038	in	in	IN	B-PP
O	1039	1047	Matrigel	Matrigel	NNP	B-NP
O	1048	1053	assay	assay	NN	I-NP
O	1054	1056	by	by	IN	B-PP
O	1057	1064	showing	show	VBG	B-VP
O	1065	1068	the	the	DT	B-NP
O	1069	1080	significant	significant	JJ	I-NP
O	1081	1091	inhibition	inhibition	NN	I-NP
O	1092	1094	of	of	IN	B-PP
O	1095	1099	bFGF	bFGF	NN	B-NP
O	1099	1100	-	-	HYPH	O
O	1100	1106	driven	drive	VBN	B-VP
O	1107	1119	angiogenesis	angiogenesis	NN	B-NP
O	1120	1123	and	and	CC	O
B-Multi-tissue_structure	1124	1129	blood	blood	NN	B-NP
I-Multi-tissue_structure	1130	1136	vessel	vessel	NN	I-NP
O	1137	1146	formation	formation	NN	I-NP
O	1146	1147	.	.	.	O

O	1148	1150	It	It	PRP	B-NP
O	1151	1154	was	be	VBD	B-VP
O	1155	1162	thought	think	VBN	I-VP
O	1163	1167	that	that	IN	B-SBAR
O	1168	1174	potent	potent	JJ	B-NP
O	1175	1189	antiangiogenic	antiangiogenic	JJ	I-NP
O	1190	1196	effect	effect	NN	I-NP
O	1197	1199	of	of	IN	B-PP
O	1200	1204	cRGD	cRGD	NN	B-NP
O	1204	1205	-	-	HYPH	I-NP
O	1205	1207	HL	HL	NN	B-NP
O	1208	1211	was	be	VBD	B-VP
O	1212	1220	probably	probably	RB	B-ADVP
O	1221	1224	due	due	JJ	B-ADJP
O	1225	1227	to	to	TO	B-PP
O	1228	1231	the	the	DT	B-NP
O	1232	1244	interference	interference	NN	I-NP
O	1245	1247	of	of	IN	B-PP
O	1248	1253	alpha	alpha	NN	B-NP
O	1253	1254	(	(	(	O
O	1254	1255	v	v	NN	B-NP
O	1255	1256	)	)	)	O
O	1256	1260	beta	beta	NN	B-NP
O	1260	1261	(	(	(	O
O	1261	1262	3	3	CD	B-NP
O	1262	1263	)	)	)	O
O	1263	1264	-	-	HYPH	B-NP
O	1264	1272	mediated	mediate	VBN	I-NP
O	1273	1284	interaction	interaction	NN	I-NP
O	1284	1285	,	,	,	O
O	1286	1295	resulting	result	VBG	B-VP
O	1296	1298	in	in	IN	B-PP
O	1299	1302	the	the	DT	B-NP
O	1303	1311	enhanced	enhance	VBN	I-NP
B-Cancer	1312	1323	antitumoral	antitumoral	JJ	I-NP
O	1324	1332	activity	activity	NN	I-NP
O	1333	1340	against	against	IN	B-PP
B-Cancer	1341	1345	SCC7	SCC7	NN	B-NP
I-Cancer	1346	1351	tumor	tumor	NN	I-NP
O	1351	1352	.	.	.	O

O	1353	1363	CONCLUSION	CONCLUSION	NN	B-NP
O	1363	1364	:	:	:	O
O	1365	1370	These	These	DT	B-NP
O	1371	1378	results	result	NNS	I-NP
O	1379	1391	demonstrated	demonstrate	VBD	B-VP
O	1392	1396	that	that	IN	B-SBAR
O	1397	1401	cRGD	cRGD	NN	B-NP
O	1401	1402	-	-	HYPH	B-NP
O	1402	1410	modified	modify	VBN	I-NP
O	1411	1418	heparin	heparin	NN	I-NP
O	1419	1429	derivative	derivative	NN	I-NP
O	1430	1438	enhanced	enhance	VBD	B-VP
O	1439	1443	anti	anti	AFX	B-NP
O	1443	1444	-	-	HYPH	I-NP
O	1444	1460	angiotherapeutic	angiotherapeutic	JJ	I-NP
O	1461	1468	effects	effect	NNS	I-NP
O	1469	1476	against	against	IN	B-PP
B-Cancer	1477	1482	solid	solid	JJ	B-NP
I-Cancer	1483	1488	tumor	tumor	NN	I-NP
O	1488	1489	,	,	,	O
O	1490	1493	and	and	CC	O
O	1494	1503	therefore	therefore	RB	B-ADVP
O	1503	1504	,	,	,	O
O	1505	1507	it	it	PRP	B-NP
O	1508	1513	could	could	MD	B-VP
O	1514	1516	be	be	VB	I-VP
O	1517	1524	applied	apply	VBN	I-VP
O	1525	1527	to	to	TO	I-VP
O	1528	1533	treat	treat	VB	I-VP
O	1534	1541	various	various	JJ	B-NP
B-Cancer	1542	1549	cancers	cancer	NNS	I-NP
O	1550	1553	and	and	CC	O
O	1554	1564	angiogenic	angiogenic	JJ	B-NP
O	1565	1573	diseases	disease	NNS	I-NP
O	1574	1576	as	as	IN	B-PP
O	1577	1578	a	a	DT	B-NP
O	1579	1585	potent	potent	JJ	I-NP
O	1586	1598	angiogenesis	angiogenesis	NN	I-NP
O	1599	1608	inhibitor	inhibitor	NN	I-NP
O	1608	1609	.	.	.	O

